Literature DB >> 10482267

Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA.

L Yen1, S M Strittmatter, R G Kalb.   

Abstract

The selective loss of neurons in Huntington's disease (HD) is caused by the abnormal expansion of the CAG triplet (>36 repeats) of the HD gene. Although the molecular events that lead to neuronal death are not clear, it is most likely that mutant HD protein operates through a "gain-of-function" mechanism. One possible therapeutic approach that does not require definition of the toxic mechanism(s) involves reduction in the levels of mutant HD protein by decreasing the quantity of translatable HD mRNA. In this report, we demonstrate the first effective destruction of the HD mRNA, using a catalytic DNA--an oligodeoxynucleotide with RNA-cleaving enzymatic activity. We show that the cleavage of HD mRNA by the catalytic DNA occurs in a sequence-specific manner, and leads to significant reduction of HD protein expression in mammalian cells. The catalytic DNAs we have developed are a valuable research tool for studying HD, and may have the therapeutic potential of reducing cellular toxicity caused by mutant HD protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482267     DOI: 10.1002/1531-8249(199909)46:3<366::aid-ana12>3.0.co;2-d

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Authors:  Steffen Schubert; Deniz C Gül; Hans-Peter Grunert; Heinz Zeichhardt; Volker A Erdmann; Jens Kurreck
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

3.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

4.  Potent Intracellular Knock-Down of Influenza A Virus M2 Gene Transcript by DNAzymes Considerably Reduces Viral Replication in Host Cells.

Authors:  Binod Kumar; Roopali Rajput; Dibya Ranjan Pati; Madhu Khanna
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

5.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

6.  Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth.

Authors:  Roger G Fahmy; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

7.  Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Authors:  Eileen M Denovan-Wright; Edgardo Rodriguez-Lebron; Alfred S Lewin; Ronald J Mandel
Journal:  Neurobiol Dis       Date:  2007-11-12       Impact factor: 5.996

8.  Mouse Huntington's disease homolog mRNA levels: variation and allele effects.

Authors:  Karen T Dixon; Jamie A Cearley; Jesse M Hunter; Peter J Detloff
Journal:  Gene Expr       Date:  2004

Review 9.  In vitro selection, characterization, and application of deoxyribozymes that cleave RNA.

Authors:  Scott K Silverman
Journal:  Nucleic Acids Res       Date:  2005-11-11       Impact factor: 16.971

10.  Systematic analysis of the role of target site accessibility in the activity of DNA enzymes.

Authors:  Graeme Doran; Muhammad Sohail
Journal:  J RNAi Gene Silencing       Date:  2006-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.